Phase II study of gp100:209-217 (210M) antigen and MART-1:26-35 (27L) antigen emulsified in montanide ISA-51 [melanoma vaccine] in patients with metastatic ocular melanoma
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Interleukin-2; Melanoma vaccine; Montanide ISA-51
- Indications Malignant melanoma
- Focus Therapeutic Use
- 16 Aug 2013 Biomarkers information updated
- 31 May 2007 New trial record.